Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC
04 Nov 2025
bởiJairia Dela Cruz
Neoadjuvant treatment with tiragolumab plus atezolizumab, with or without chemotherapy, is feasible in advanced resectable non-small cell lung cancer (NSCLC), having an acceptable safety profile and yielding major pathologic response (MPR) rates comparable to that observed with other perioperative immunotherapy plus chemotherapy regimens, according to the phase II SKYSCRAPER-05 trial.